Company Profile
Morphic Holding, Inc. Stock Price, News & Analysis
- Ticker:
- MORF
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for MORF.
Company overview
Business overview
Morphic was an integrin-focused biotechnology company with a pipeline in inflammatory and gastrointestinal disease before being acquired by Eli Lilly.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ prior to acquisition, it sat in specialty biotechnology.
Business Model Characteristics
The company was driven by novel biology, early clinical data, and the value of its integrin platform.
Position Within the Biotechnology Landscape
Morphic was a targeted immunology name and now belongs to biotech M&A history.
Future catalysts
Morphic is now mostly a closeout and acquisition story after the Lilly deal, so the catalysts are integration and any remaining corporate milestone. The market is not treating it like a live standalone pipeline name anymore.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Morphic Holding, Inc. do?
Morphic was an integrin-focused biotechnology company with a pipeline in inflammatory and gastrointestinal disease before being acquired by Eli Lilly.
On which exchange is MORF stock listed?
Morphic Holding, Inc. (MORF) is associated with NASDAQ, United States, Biopharma.
What is Morphic?
Morphic is now mostly a closeout and acquisition story after the Lilly deal, so the catalysts are integration and any remaining corporate milestone.
Which conditions is Morphic Holding, Inc. targeting with Morphic?
Morphic is now mostly a closeout and acquisition story after the Lilly deal, so the catalysts are integration and any remaining corporate milestone.
How does Morphic Holding, Inc. describe recent progress with Morphic?
Morphic is now mostly a closeout and acquisition story after the Lilly deal, so the catalysts are integration and any remaining corporate milestone.
What is Lilly?
Morphic was an integrin-focused biotechnology company with a pipeline in inflammatory and gastrointestinal disease before being acquired by Eli Lilly.
What should investors watch for with Lilly?
Morphic is now mostly a closeout and acquisition story after the Lilly deal, so the catalysts are integration and any remaining corporate milestone.
What future catalysts are investors watching for Morphic Holding, Inc.?
Morphic is now mostly a closeout and acquisition story after the Lilly deal, so the catalysts are integration and any remaining corporate milestone. The market is not treating it like a live standalone pipeline name anymore.